evaluated and, if necessary, modified for each new assay. Collaboration between laboratories and physicians is essential in the setting up of new immunoassays.

Abbott Laboratories provided assay reagent and the assay system without charge.

## References

- Howles CM, Macnamee MC. Endocrine monitoring for assisted human conception. Br Med Bull 1990;46:616–27.
- Balos O, Lundkvist O, Wide L, Bergh T. Ultrasonographical and hormonal description of the normal ovulatory menstrual cycle. Acta Obstet Gynecol Scand 1994;73:790–6.
- Muse MD, Wilson EA. Monitoring ovulation: use of biochemical and biophysical parameters. Semin Reprod Endocrinol 1986;4:301–9.
- Fossum G, Vermesh M, Kletzky OA. Biochemical and biophysical indices of follicular development in spontaneous and stimulated ovulatory cycles. Obstet Gynecol 1990;75:407–11.
- Sushanek E, Huderer K, Dobec D, Hlavati V, Simunic V, Grizelj V. Number of follicles, oocytes and embryos in human in vitro fertilization is relative to serum estradiol and progesterone patterns during different types of ovarian hyperstimulation. Eur J Obstet Gynecol Reprod Biol 1994;56:121–7.
- Dor J, Seidman DS, Ben-Shlomo I, Levran D, Karasik A, Mashiach S. The prognostic importance of the number of oocytes retrieved and estradiol levels in poor and normal responders in in vitro fertilization (IVF) treatment. J Assist Reprod Genet 1992;9:228–32.
- Levran D, Lopata A, Nayudu PL, Martin MJ, McBain JC, Bayly CM, et al. Analysis of the outcome of in-vitro fertilization in relation to the timing of human chorionic gonadotropin administration by the duration of estradiol rise in stimulated cycles. Fertil Steril 1985;44:335–41.
- Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58: 249–61.
- Morris RS, Paulson RJ, Sauer MV, Lobo RA. Predictive value of serum estradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Hum Reprod 1995;10:811–4.
- Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intra-Fallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992;58:888–96.
- Licciardi FL, Liu HC, Rosenwaks Z. Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril 1995;64:991–4.
- Spencer CA, Takeuchi M, Kararosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem 1997;42:140–5.
- Taieb J, Benattar C, Birr AS, Lindenbaum A. Limitations of steroid determination by direct immunoassay. Clin Chem 2002;48:583–5.
- 14. Taieb J, Sarnel C, Benattar C, Lindenbaum A. A new technique for measuring 17β-estradiol using Kryptor (Cis Bio International): utilization to monitor ovulation stimulation. Ann Biol Clin 2000;58:71–9.
- Taieb J, Benattar C, Chalas J, Messaoudi C, Lindenbaum A. Comparaison de cinq techniques de dosage direct du 17β estradiol. Immunoanal Biol Spec 1997;12:267–74.
- Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–10.
- Schroder V, Thode J. Six direct radioimmunoassays of estradiol evaluated. Clin Chem 1988;34:949–52.
- Lee CS, Smith NM, Kahn SN. Analytical variability and clinical significance of different assays for serum estradiol. J Reprod Med 1991;36:156–60.
- Mikkelsen AL, Borggaard B, Lebech PE. Results of serial measurement of estradiol in serum with six different methods during ovarian stimulation. Gynecol Obstet Invest 1996;41:34–40.
- Tummon I, Stemp J, Rose C, Vandenberghe H, Bany B, Tekpetey F, et al. Precision and method bias of two assays for oestradiol: consequences for decisions in assisted reproduction. Hum Reprod 1999;14:1175–7.
- Büttner J. Philosophy of measurement by means of immunoassays. Scand J Clin Lab Invest 1991;51(Suppl 205):11–20.
- Potischman N, Falk RT, Laiming VA, Siiteri PK, Hoover RN. Reproducibility of laboratory assays for steroid hormone and sex hormone-binding globulin. Cancer Res 1994;54:5363–7.
- Franek M. Structural aspects of steroid-antibody specificity. J Steroid Biochem 1987;28:95–108.
- Grover PK, Odell WD. Specificity of antisera to sex steroids I. The effect of substitution and stereochemistry. J Steroid Biochem 1977;8:121–6.
- 25. Cook NC, Read GF. Oestradiol measurement in women on oral replacement

therapy: the validity of commercial test kits. Br J Biomed Sci 1995;52:97-101.

- Yuzpe AA, Nisker JA, Kaplan BR, Tummon IS, Auckland J. Nafarelin acetate for down regulation in in vitro fertilization. J Reprod Med 1995;40:83–8.
- Cohen J. A coefficient of agreement for nominal scales. Educ Psych Meas 1960;20:37–46.
- Diver MJ, Nisbet JA. Warning on plasma oestradiol measurement. Lancet 1987;15:17–35.

Fast Colorimetric Method for Measuring Urinary Iodine, Daniella Gnat,<sup>1</sup> Ann D. Dunn,<sup>2</sup> Samar Chaker,<sup>1</sup> Francois Delange,<sup>1,3</sup> Francoise Vertongen,<sup>1</sup> and John T. Dunn<sup>2,3\*</sup> (<sup>1</sup> Centre Hospitalier Universitaire St. Pierre, Free University of Brussels, 1000 Brussels, Belgium; <sup>2</sup> Division of Endocrinology, Department of Medicine, University of Virginia, Charlottesville, VA 22908; <sup>3</sup> International Council for the Control of Iodine Deficiency Disorders, Box 801416, University of Virginia Health System, Charlottesville, VA 22908; \* author for correspondence: fax 434-243-9195, e-mail jtd@virginia.edu)

International groups recommend the following median urinary iodine concentration as the best single indicator of iodine nutrition in populations: severe deficiency, 0–0.15  $\mu$ mol/L (0–19  $\mu$ g/L); moderate deficiency, 0.16–0.38  $\mu$ mol/L (20–49  $\mu$ g/L); mild deficiency, 0.40–0.78  $\mu$ mol/L (50–99  $\mu$ g/L); optimal iodine nutrition, 0.79–1.56  $\mu$ mol/L (100–199  $\mu$ g/L); more than adequate iodine intake, 1.57–2.36  $\mu$ mol/L (200–299  $\mu$ g/L); and excessive iodine intake,  $\geq$ 2.37  $\mu$ mol/L ( $\geq$ 300  $\mu$ g/L) (1). The range in which the median falls is more important than the precise number (2, 3).

Many methods for assessing urinary iodine exist (3-8), most based on the Sandell–Kolthoff reaction (9), in which iodide catalyzes the reduction of ceric ammonium sulfate (yellow) to the colorless cerous form in the presence of arsenious acid. Although iodide is the chemical form for both the catalytic reaction and in urine, some preliminary treatment is needed to rid urine of impurities, most commonly by acid digestion (3, 5). We have extended previous approaches (5, 6, 10) with improved conditions and here present a new method ("Fast B") that is rapid, inexpensive, reliable, and flexible.

The equipment required for the Fast B method includes a heating block, Pyrex test tubes ( $13 \times 100$  mm), two fixed-volume pipettes (0.5 mL and 1.0 mL), one adjustable pipette ( $0-200 \ \mu$ L), and a multipet (Eppendorf) for quick reagent volume additions of 0.125 and 0.1 mL. The basic chemicals used are potassium iodate, arsenic trioxide, ammonium persulfate, ammonium cerium(IV) sulfate dihydrate, sodium chloride, ferroine, and sulfuric acid.

The solutions used in the assay are as follows:

- (a) Ammonium persulfate solution: 114.0 g of ammonium persulfate made up to 500 mL with water (stable for at least 1 month at 20−25 °C away from light)
- (b) 2.5 mol/L H<sub>2</sub>SO<sub>4</sub>

- (c) Arsenious acid solution: 10 g of As<sub>2</sub>O<sub>3</sub>, 50 g of NaCl, 400 mL of 2.5 mol/L H<sub>2</sub>SO<sub>4</sub>, and 600 mL water; heated gently to dissolve, diluted to a final volume of 2 L, filtered, and stored in a dark bottle away from light at 20–30 °C (stable for at least 6 months)
- (*d*) Sodium chloride: 40 g in 200 mL of water
- (e) 10.8 mol/L  $H_2SO_4$
- (f) Ceric ammonium sulfate: 16 g in 1 L of 1.35 mol/L H<sub>2</sub>SO<sub>4</sub> (stable for more than 6 months in a dark bottle)
- (g) Iodine calibrators: working solutions of 0.40  $\mu$ mol/L (50  $\mu$ g/L), 0.79  $\mu$ mol/L (100  $\mu$ g/L), and 2.37  $\mu$ mol/L (300  $\mu$ g/L), prepared from concentrated iodate solution [788  $\mu$ mol/L (100 mg/L)], made by dissolving 168.5 mg of potassium iodate in 1 L of water. Working solutions of other concentrations can be prepared as needed
- (h) Ferroine/arsenious acid solution: prepared shortly before use by mixing 2 mL of 10.8 mol/L H<sub>2</sub>SO<sub>4</sub>, 2 mL of arsenious acid solution, 4 mL of 200 g/L sodium chloride, and 2 mL of ferroine

We obtained fresh samples from healthy individuals and hospitalized patients in Brussels and frozen samples from epidemiologic studies in Europe and Africa. The urine samples were not treated with acid, but thymol crystals had been added to some of the samples in their country of origin before transfer to the laboratory. Results were compared with those obtained with the Technicon AutoAnalyzer II (Bayer/Technicon Instruments) (11) in use in our Brussels laboratory for more than 20 years and periodically subjected to routine external quality control.

We investigated several conditions to improve the previously described method (10), including use of ammonium persulfate in place of the more toxic chloric acid, a longer time for color development, and smaller sample volumes.

The final procedure developed is as follows. Each tube, containing 0.15 mL of urine or of calibrator and 1.0 mL of ammonium persulfate solution, is heated for 1 h in the block at 100 °C. After the solution is cooled at room temperature, 0.5 mL of arsenious acid solution is added to each tube and mixed on a vortex-mixer. At least 15 min later, 0.125 mL of fresh ferroine-arsenious acid solution is added. Tubes are mixed on a vortex-mixer and ranged in racks as follows: three calibrators  $[0.40 \,\mu mol/L \,(50 \,\mu g/L),$ 0.79  $\mu$ mol/L (100  $\mu$ g/L), and 2.37  $\mu$ mol/L (300  $\mu$ g/L)], followed by the urine samples and controls, and at the end, a second set of the same three calibrators. Each batch contains a total of 45-55 tubes, including samples, blanks, and controls. To each tube we rapidly add 0.1 mL of ceric ammonium sulfate solution with the multipipetter, with rapid shaking of each rack, and observe all tubes closely. After an initial blue color, samples first turn purple and then orange/brown. The speed of the color change depends on the iodine concentration. As each sample turns purple, it is placed in another rack in order of color change after addition of the ceric ammonium sulfate. Thus, all tubes, including calibrators and samples, are now ranked in order of color change. We then count the number of samples falling into each of the four categories [>2.37  $\mu$ mol/L (>300  $\mu$ g/L), 0.79–2.37  $\mu$ mol/L (100–300  $\mu$ g/L), 0.40–0.78  $\mu$ mol/L (50–99  $\mu$ g/L), and <0.40  $\mu$ mol/L (<50  $\mu$ g/L)] from the position of each tube relative to the positions of the calibrators.

When we compared the results obtained for 286 urine samples by the Fast B method with the results obtained with the AutoAnalyzer II method (Table 1), 275 (96.2%) were placed in the correct category by Fast B. Of the 11 discordant values, all were close to range cutoffs: 6 were false positives (samples with concentrations of 0.63, 0.71, 0.74, and 0.76  $\mu$ mol/L by the AutoAnalyzer II method were placed in the 0.79–2.37  $\mu$ mol/L range by the Fast B, and samples with concentrations of 2.22 and 2.24  $\mu$ mol/L were placed in the >2.37 range), and 5 were false negatives (samples with concentrations of 0.83 and 0.83  $\mu$ mol/L by the AutoAnalyzer II method were placed in the >2.37 range), and 5 were false negatives (samples with concentrations of 0.83 and 0.83  $\mu$ mol/L by the AutoAnalyzer II method were placed in the 0.40–0.78 range by the Fast B, and samples with concentrations of 2.46, 2.52, and 2.39  $\mu$ mol/L were placed in the 0.79–2.37 range).

Approximately 45 samples, including 39 unknowns, can be handled in each analytical run. The color change is readily recognized visually. Under our conditions, samples with an iodine concentration  $>2.37 \mu mol/L$  (>300 $\mu$ g/L) change color in <2 min, those with a concentration of 2.37  $\mu$ mol/L (300  $\mu$ g/L) change color at ~2 min, those with a concentration of 0.79  $\mu$ mol/L (100  $\mu$ g/L) change color at  $\sim 5$  min, those with a concentration of 0.40  $\mu$ mol/L (50  $\mu$ g/L) change color at ~10 min, and those with a concentration of 0.08  $\mu$ mol/L (10  $\mu$ g/L) change color at  $\sim 40$  min. For most purposes, it is satisfactory simply to record the number that have not changed before the 0.40  $\mu$ mol/L (50  $\mu$ g/L) calibrator and not wait. We have focused on calibrators that bracket the recommended ranges for defining iodine nutrition (1). Other calibrators between 0.40 and 2.37  $\mu$ mol/L can be used to define other ranges of interest. Our experiments were conducted at a laboratory temperature of 20-25 °C. The speed of the Sandell-Kolthoff reaction is influenced by temperature and may need to be carried out at controlled temperatures in hot or cold climates (12).

From three urine samples with different iodine concentrations [0.30  $\mu$ mol/L (38  $\mu$ g/L), 0.76  $\mu$ mol/L (96  $\mu$ g/L), and 2.01  $\mu$ mol/L (255  $\mu$ g/L), respectively, authenticated by the AutoAnalyzer], we ran 10 aliquots of each sample separately in the same run; all 30 were correctly placed in the three categories: <0.40  $\mu$ mol/L (<50  $\mu$ g/L), 0.40–0.78

## Table 1. Comparison of iodine concentrations in 286 urine samples measured by Fast B and AutoAnalyzer II.

lodine concentration range, μmol/L (μg/L)	No. of samples	
	Fast B	AutoAnalyzer
<0.40 (<50)	39	39
0.40-0.78 (50-99)	74	76
0.79–2.37 (100–300)	112	109
>2.37 (>300)	61	62

 $\mu$ mol/L (50–99  $\mu$ g/L), and 0.79–2.37 $\mu$ mol/L (100–300  $\mu$ g/L). We also analyzed an aliquot of each of the three samples for 13 consecutive days (a total of 39 samples); 38 of the 39 (97.5%) were placed correctly, and the 39th was placed in the category immediately above the correct category.

We diluted a urine sample containing 6.3  $\mu$ mol/L iodine to give the following concentrations: 3.15, 2.10, 1.58, 1.05, 0.79, 0.63, and 0.53  $\mu$ mol/L. The Fast B placed each in the correct range except the last, which was classified as <0.40  $\mu$ mol/L. For comparison, the Auto-Analyzer gave respective values of >1.97, >1.97, 1.45, 1.03, 0.79, 0.61, and 0.54  $\mu$ mol/L. We added KIO<sub>3</sub> to a low-iodine sample (0.35  $\mu$ mol/L) to produce samples containing 0.67, 0.98, 1.30, and 1.62  $\mu$ mol/L iodine. Measurement by Fast B placed each in the correct range. For comparison, the Auto-Analyzer gave values of 0.64, 1.03, 1.34, and 1.54  $\mu$ mol/L, respectively.

Ascorbic acid at concentrations of 0, 3.78, 7.96, or 15.92 mmol/L added to a sample containing 1.15  $\mu$ mol/L (146  $\mu$ g/L) iodine did not change the iodine concentration measured by the AutoAnalyzer (1.14–1.15  $\mu$ mol/L) or by Fast B [remaining in the 0.79–1.18  $\mu$ mol/L (100–150  $\mu$ g/L) category]; for this experiment, other KIO<sub>3</sub> calibrators were used to create the category of 0.79–1.18  $\mu$ mol/L (100–150  $\mu$ g/L).

No change in iodine concentration was detected by either the AutoAnalyzer or Fast B after the addition of potassium thiocyanate at concentrations of 0.172, 0.344, or 0.688 mmol/L or of D-glucose up to 56 mmol/L (10.14 g/L).

The placement of values within the ranges described here satisfies most epidemiologic purposes (1) and is more cost-effective than analyzing and reporting individual samples. One technician can easily measure 200 samples in a working day, and depending on salaries, the cost may be less than US \$0.10/sample. One of us (D.G.) trained two technicians from a developing country in African to be proficient in the method after 3 days of instruction and practice. The investment in equipment is low, and except for pipettes, the only instrument is the heating block, which might be replaced by a boiling water bath if necessary.

In conclusion, the Fast B method described here is rapid, simple, reliable, flexible, and inexpensive and provides an attractive means for assessing iodine nutrition in populations, especially in developing countries.

We thank the Micronutrient Initiative (Ottawa, Canada) for financial support, and colleagues in the International Council for the Control of Iodine Deficiency Disorders (ICCIDD) for providing samples and helpful discussion.

## References

laboratory evaluation of endemic goiter. In: Dunn JT, Pretell EA, Daza CH, Viteri FE, eds. Towards the eradication of endemic goiter, cretinism, and iodine deficiency. Washington: Pan American Health Organization, 1986: 115–29.

- Dunn JT, Crutchfield HE, Gutekunst R, Dunn AD. Methods for measuring iodine in urine. Charlottesville, VA: International Council for Control of Iodine Deficiency Disorders, 1993.
- Standardization of ultrasound and urinary iodine determination for assessing iodine status: report of a technical consultation. IDD Newslett 2000;16: 19–23.
- Pino S, Fang SL, Braverman LE. Ammonium persulfate: a safe alternative oxidizing reagent for measuring urinary iodine. Clin Chem 1996;42:239–43.
- Dunn JT, Crutchfield HE, Gutekunst R, Dunn AD. Two simple methods for measuring iodine in urine. Thyroid 1993;3:119–23.
- Rendl J, Bier D, Groh T, Reiners C. Rapid urinary iodide test. J Clin Endocrinol Metab 1998;83:1007–12.
- Ohashi T, Yamaki M, Pandav CS, Karmarkar MG, Irie M. Simple microplate method for determination of urinary iodine. Clin Chem 2000;46:529–36.
- Sandell EB, Kolthoff IM. Micro determination of iodine by a catalytic method. Mikrochem Acta 1937;1:9–25.
- Dunn JT, Myers HE, Dunn AD. Simple method for assessing urinary iodine, including preliminary description of a new rapid technique ("Fast B"). Exp Clin Endocrinol Diabetes 1998;106(Suppl 3):1005–7.
- Riley M, Gochman N. A fully automated method for the determination of serum protein-bound iodine. Tarrytown, NY: Technicon Symposium, 1964.
- Dung NT, Wellby ML. Effect of high room temperature on urinary iodine assay. Clin Chem 1997;43:1084–5.

Effects of Midstream Collection and the Menstrual Cycle on Urine Particles and Dipstick Urinalysis among Healthy Females, *Mie Morimoto*,<sup>1\*</sup> *Hidekatsu Yanai*,<sup>2</sup> *Kenichi Shukuya*,<sup>3</sup> *Hitoshi Chiba*,<sup>2</sup> *Kunihiko Kobayashi*,<sup>4</sup> and Kazu*hiko Matsuno*<sup>1</sup> (<sup>1</sup> College of Medical Technology, Hokkaido University, North-12, West-5, Sapporo 060-0812, Japan; Departments of <sup>2</sup> Laboratory Medicine and <sup>4</sup> Pediatrics, Hokkaido University School of Medicine, North-14, West-5, Sapporo 060-8648, Japan; <sup>3</sup> Department of Laboratory Medicine, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan; \* author for correspondence: fax 81-11-706-4916, e-mail mie@cme.hokudai.ac.jp)

For urinalysis, midstream collection is recommended (1-3). Health-associated reference limits for leukocyte and erythrocyte counts in female urine are important for detecting hematuria, pyuria, and urinary tract infection (3). To understand the effects of urinary collection and the menstrual cycle on urinalysis, we examined first-stream and midstream urine samples from healthy female students with use of an automated dipstick reader and the fully automated urine cell analyzer, UF-100.

Specimens were obtained from 64 healthy female students (age range, 18–20 years) at the College of Medical Technology. All were asymptomatic and had no extant urologic disease. They were instructed to collect only first and midstream urine samples in sterile containers at the same time and not to wipe or spread the labia. The volume of the first urine was measured, and the specimen was analyzed within 2 h. The students provided written, informed consent to participate in the study as well as information about their menstrual cycles. Specimens were classified into four groups according to the number of days after menstruation as follows: menstrual (1–7 days

International Council for the Control of Iodine Deficiency Disorders, WHO, UNICEF. Assessment of iodine deficiency disorders and monitoring their elimination. A guide for programme managers, 2nd ed. Geneva, Switzerland: World Health Organization, 2001.

<sup>2.</sup> Bourdoux P, Thilly C, Delange F, Ermans AM. A new look at old concepts in